Carolina Bekker-Mendez

Dr. Carolina Bekker-Mendez

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MPMaría Luisa Perez-Saldivar
María Luisa Perez-Saldivar
AFArturo Fajardo-Gutiérrez
Arturo Fajardo-Gutiérrez
RBRoberto Bernáldez-Ríos
Roberto Bernáldez-Ríos
AMArmando Martínez-Avalos
Armando Martínez-Avalos
AMAurora Medina-Sanson
Aurora Medina-Sanson
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Background: Worldwide, acute leukemia is the most common type of childhood cancer. It is particularly common in the Hispanic populations residing in the United States, Costa Rica, and Mexico City. The objective of this study was to determine the incidence of acute leukemia in children who were diagnosed and treated in public hospitals in Mexico City. Methods: Included in this study were those children, under 15 years of age and residents of Mexico City, who were diagnosed in 2006 and 2007 with leukemia, as determined by using the International Classification of Childhood Cancer. The average annual incidence rates (AAIR), and the standardized average annual incidence rates (SAAIR) per million children were calculated. We calculated crude, age- and sex-specific incidence rates and adjusted for age by the direct method with the world population as standard. We determined if there were a correlation between the incidence of acute leukemias in the various boroughs of Mexico City and either the number of agricultural hectares, the average number of persons per household, or the municipal human development index for Mexico (used as a reference of socio-economic level). Results: Although a total of 610 new cases of leukemia were registered during 2006-2007, only 228 fit the criteria for inclusion in this study. The overall SAAIR was 57.6 per million children (95% CI, 46.9-68.3); acute lymphoblastic leukemia (ALL) was the most frequent type of leukemia, constituting 85.1% of the cases (SAAIR: 49.5 per million), followed by acute myeloblastic leukemia at 12.3% (SAAIR: 6.9 per million), and chronic myeloid leukemia at 1.7% (SAAIR: 0.9 per million). The 1-4 years age group had the highest SAAIR for ALL (77.7 per million). For cases of ALL, 73.2% had precursor B-cell immunophenotype (SAAIR: 35.8 per million) and 12.4% had T-cell immunophenotype (SAAIR 6.3 per million). The peak ages for ALL were 2-6 years and 8-10 years. More than half the children (58.8%) were classified as high risk. There was a positive correlation between the average number of persons per household and the incidence of the pre-B immunophenotype (Pearson's r, 0.789; P = 0.02). Conclusions: The frequency of ALL in Mexico City is among the highest in the world, similar to those found for Hispanics in the United States and in Costa Rica.

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
EJEthel Zulie Jaimes-Reyes
Ethel Zulie Jaimes-Reyes
JAJosé Arellano-Galindo
José Arellano-Galindo
XGXochiketzalli García-Jiménez
Xochiketzalli García-Jiménez
HTHéctor Manuel Tiznado-García
Héctor Manuel Tiznado-García
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Our aim in this paper is to describe the results of treatment of acute lymphoblastic leukaemia (ALL) in Mexican children treated from 2006 to 2010 under the protocol from the Dana-Farber Cancer Institute (DFCI) 00-01. The children were younger than 16 years of age and had a diagnosis of ALL denovo. The patients were classified as standard risk if they were 1–9.9 years old and had a leucocyte count 100 × 109/L. The poor outcomes were associated with toxic death during induction, complete remission, and relapse. These factors remain the main obstacles to the success of this treatment in our population.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
EMEnrique Miranda-Peralta
Enrique Miranda-Peralta
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
IOIrma Olarte-Carrillo
Irma Olarte-Carrillo
FGFrancisco Xavier Guerra-Castillo
Francisco Xavier Guerra-Castillo
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico has one of the highest incidences of childhood leukemia worldwide and significantly higher mortality rates for this disease compared with other countries. One possible cause is the high prevalence of gene rearrangements associated with the etiology or with a poor prognosis of childhood acute lymphoblastic leukemia (ALL). The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, andMLLrearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City. Patients were recruited from eight public hospitals during 2010–2012. A total of 282 bone marrow samples were obtained at each child’s diagnosis for screening by conventional and multiplex reverse transcription polymerase chain reaction to determine the gene rearrangements. Gene rearrangements were detected in 50 (17.7%) patients.ETV6-RUNX1was detected in 21 (7.4%) patients,TCF3-PBX1in 20 (7.1%) patients,BCR-ABL1in 5 (1.8%) patients, andMLLrearrangements in 4 (1.4%) patients. The earliest deaths occurred at months 1, 2, and 3 after diagnosis in patients withMLL, ETV6-RUNX1, andBCR-ABL1gene rearrangements, respectively. Gene rearrangements could be related to the aggressiveness of leukemia observed in Mexican children.

1 September 1995 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
GVGilberto Vargas-Alarcón
Gilberto Vargas-Alarcón
JGJulio Granados
Julio Granados
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
JAJorge Alcocer‐Varela
Jorge Alcocer‐Varela
DADonato Alarcón‐Segovia
Donato Alarcón‐Segovia
Click on the article title to read more.

1 November 2016 in Archives of Medical Research
Verified
Journal Article
Closed access
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
DBDiego Alberto Bárcenas-López
Diego Alberto Bárcenas-López
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE

18 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
AGAna Elena Gil-Hernández
Ana Elena Gil-Hernández
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
AFArturo Fajardo-Gutiérrez
Arturo Fajardo-Gutiérrez
AMAurora Medina-Sansón
Aurora Medina-Sansón
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study was to identify if overweight and obesity are predictors of early mortality and relapse in Mexican children with ALL. A multicenter cohort study was conducted. ALL children younger than 15 years old were included and followed-up during the first 24 months after diagnosis. Overweight and obesity were classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Early mortality and early relapses were the main outcomes. A total of 1070 children were analyzed. Overweight/obesity at diagnosis were predictors of early mortality (WHO: HR = 1.4, 95%CI:1.0–2.0; CDC: HR = 1.6, 95%CI:1.1–2.3). However, no associations between overweight (WHO: HR = 1.5, 95%CI:0.9–2.5; CDC: HR = 1.0; 95% CI:0.6–1.6) and obesity (WHO: HR = 1.5, 95%CI:0.7–3.2; CDC: HR = 1.4; 95%CI:0.9–2.3) with early relapse were observed. Overweight and obese patients embody a subgroup with high risk of dying during leukemia treatment.